VivoFuse 3D Optical BLI and MRI Fusion


3D Optical BLI and MRI Fusion

VivoFuseTM 3D Optical BLI and MRI Fusion

Streamline your research with our cost-effective, top quality, multi-modality imaging tools

Bioluminescence Imaging (BLI) provides valuable and precise methods to assess biological functional information, including tumor burden and biological behavior in mice metastatic models. In order to take advantage of multimodal approaches which combine the strengths of molecular and morphological imaging modalities, accurate signal localization may be required, which is only possible with 3D optical reconstruction.

IVIS SpectrumCT® (PerkinElmer) offers combined optical and CT information, enabling 3D optical tomography for FLI and BLI, overcoming the limitations of the current 2D-only devices (PMID: 17477722). However, since CT only provides limited soft tissue contrast, additional information is highly desirable for improved anatomical localization. MRI is the superior method when imaging soft tissue—especially for oncological studies—where in addition to tumor location and morphology, valuable information such as vascularization, amount of necrosis, cellularity as well as permeability and perfusion can be extracted from the images, providing valuable information when assessing therapeutic effectiveness in metastatic tumor models

Aspect Imaging’s VivoFuseTM solution is a novel optical and MRI fusion technique based on a proprietary animal transport system developed by Dr. Sebastian Gehrig, Department of Pharmaceutical Chemistry, Centre of Pharmaceutical Sciences, University of Vienna, Austria. This opens the door for the BLI optical research community to fuse optical data with MRI data and take advantage of the exceptional soft tissue image quality provided by MRI, in a highly affordable and cost-effective package. Our new animal transport system is compatible with the M3 and M7 compact MRI systems and is also fully compatible with IVIS SpectrumCT®, manufactured by PerkinElmer, Inc. allowing precise co-localization between 3D optical and MRI data. The fused data is presented through a PerkinElmer IVIS SpectrumCT® system.

Design and Software

Aspect Imaging M3 compact MRI was specifically designed with simplicity in mind, making MRI accessible to virtually any lab (no need for RF shielding, cryogens and MRI expertise). The system is compact and safe, with no fringe field, allowing it to be placed anywhere in the lab area, next to other imaging modalities, or behind the pathogen-free barrier.

Aspect Imaging’s unique compact MRI systems utilize one-touch MRI, an intuitive user-friendly interface that operates both the M3™ and M7™. This unique software has been developed and manufactured to provide a straightforward and reasonably simple-to-operate workstation, so that anyone can operate the MRI. Additionally, the system is built for flexibility and mobility, allowing the station be placed in practically any research facility.

CT26 therapy resistant tumor residues – clearly allocated by MRI to Pancreatic area and intraabdomianl fat in lower abdomen.

Click to view –
Combined diffuse light imaging
tomographic (DLIT) and MRI

VivoFuse™ developed by
Dr. Sebastian Gehrig, 
Department of Pharmaceutical Chemistry
Centre of Pharmaceutical Sciences,
 University of Vienna

Images generated by:
Dr. Sebastian Gehrig MMCT Lab Prof. M.Ogris
Department of Pharmaceutical Chemistry
Centre of Pharmaceutical Sciences, University of Vienna Althanstraße 14,
A-1090 Vienna, Austria


Contact Us

  • This field is for validation purposes and should be left unchanged.

Contact us

Font Resize